BeStock  
Stocks › Biotechnology › LBRX

LB Pharmaceuticals LBRX

US equityMarket cap rank #3009Biotechnology
$38.85 −$1.19 (-2.97%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $38.85 0.00%
Open$39.53
Prev close$40.04
Day range$38.57 – $40.67
Volume303.1K
Market cap$1.26B
P/E (TTM)38.3
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership104.8%-8.33 pts vs. prior quarter
Institutions holding161+14 vs. prior quarter
Insider trades (recent)28 buys / 8 sellsNet buying
Short interest19.22% of floatDays to cover 18.0 · as of 30 Oct 2026
Short-sale volume share18.4%5-day average of daily volume

Short-sale volume as % of daily volume

13%20%27%34%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$5.02M (13 inflow days, 7 outflow days).

Net flow by order size, last 20 sessions

+$4.0MSuper+$1.0MBig+$1.8MMid+$4.3MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 33.8% of shares outstanding.

Largest holders

  • Deep Track Capital, LP10.36%
  • BlackRock7.25%
  • RA Capital Management, L.P.6.82%
  • Trails Edge Capital Partners, LP4.71%
  • Commodore Capital LP4.63%
  • J.P. Morgan Asset Management, Inc.4.52%
  • TCG Crossover Management, LLC4.47%
  • Caligan Partners, LP4.44%

By investor type

  • Hedge Fund34.29%
  • VC/PE Fund34.15%
  • Mutual Fund32.06%
  • Public Company3.08%
  • Individual/Insider0.73%
  • Sovereign Wealth Fund0.50%
  • Private Company0.47%
  • Government Pension Fund0.16%

Reported short interest has risen from 15.98% to 19.22% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +915,005 3.4%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +284,233 0.9%
UBS Asset Management Mutual Fund 2026/Q3 +135,195 0.7%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +128,715 3.4%
State Street Global Advisors Mutual Fund 2026/Q3 +103,377 2.2%
BNP Paribas Financial Markets SNC Private Company 2026/Q3 +80,710 0.5%
Morgan Stanley Public Company 2026/Q3 +65,225 0.4%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +65,225 0.4%
JPMorgan Chase & Co. Public Company 2026/Q3 +49,625 0.3%
Invesco Capital Management LLC Mutual Fund 2026/Q3 +36,420 0.1%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +45,220 0.1%
Boothbay Fund Management, LLC Hedge Fund 2026/Q3 +275,675 0.9%
BlackRock Mutual Fund 2026/Q3 +263,460 8.5%
Trails Edge Capital Partners, LP Hedge Fund 2026/Q3 +203,660 4.7%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +201,423 1.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
8 Oct 2026 Joseph Miller Chief Financial Officer Other Derivative Acquisition +200,000 $37.22 200,000
8 Oct 2026 Susan Kozauer Chief Medical Officer Other Derivative Acquisition +200,000 $37.22 200,000
29 Jul 2026 David Kroin Open Market Derivative Acquisiti +286,205 $0.00 664,649
8 Jun 2026 Zachary Prensky Intent to Sell (Form 144) -16,500 $29.49 –
2 Jun 2026 Robert Richard Ruffolo Independent Director Other Derivative Acquisition +10,000 $27.95 10,000
2 Jun 2026 Ran Nussbaum Independent Director Other Derivative Acquisition +10,000 $27.95 10,000
2 Jun 2026 William Kane Independent Director Other Derivative Acquisition +10,000 $27.95 10,000
2 Jun 2026 Scott Garland Independent Chairperson Other Derivative Acquisition +10,000 $27.95 10,000
2 Jun 2026 Rebecca Luse Independent Director Other Derivative Acquisition +10,000 $27.95 10,000
2 Jun 2026 Rekha Hemrajani Independent Director Other Derivative Acquisition +10,000 $27.95 10,000
2 Jun 2026 Robert Lenz Independent Director Other Derivative Acquisition +12,500 $27.95 12,500
5 Mar 2026 Robert Lenz Independent Director Other Derivative Acquisition +20,000 $23.78 20,000
5 Feb 2026 Deep Track Capital, LP Open Market Derivative Acquisiti +472,369 $0.00 93,925
9 Dec 2025 Kaya Pai Panandiker Chief Commercial Officer Other Derivative Acquisition +195,000 $21.36 195,000
11 Sep 2025 Pontifax Venture Capital Private Acquisition +1,000,000 $15.00 1,000,000
11 Sep 2025 Pontifax Venture Capital Derivative Exercise and Retained +411,681 – 1,000,000
11 Sep 2025 Deep Track Capital, LP Private Acquisition +2,666,666 $15.00 666,666
11 Sep 2025 Deep Track Capital, LP Derivative Exercise and Retained +686,138 – 666,666
11 Sep 2025 Deep Track Capital, LP Initial Statement of Beneficial +0 – 666,666
9 Sep 2025 Robert Richard Ruffolo Independent Director Derivative Sale to Issuer -13,266 – –

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 6,199,068 19.2% 18.0
15 Oct 2026 5,564,315 17.2% 12.1
30 Sep 2026 6,010,646 18.6% 14.5
15 Sep 2026 5,617,182 17.4% 21.5
31 Aug 2026 5,278,529 16.4% 19.9
14 Aug 2026 5,156,413 16.0% 12.4

Discussion

No comments yet — be the first to weigh in on LBRX.

Sign in to join the discussion.

Scroll to Top